For coronavirus, there are various therapeutic regimens under trial. Remdesivir has shown promise in initial studies for treating COVID-19 \[[@CR1]\]. The mechanism of action for remdesivir has been studied in vivo and in vitro \[[@CR1]\]. It acts by delaying the chain termination of RNA synthesis through competing with ATP for incorporation \[[@CR1]\]. It has been studied mainly for the Ebola virus and respiratory syncytial virus, but the broad mechanism of action can be helpful in the treatment for SARS-CoV2 \[[@CR1]\]. With the use of precision medicine, we can prevent, mitigate, and provide personalized pharmacologic treatment to the patients \[[@CR2], [@CR3]\].

Remdesivir is a substrate of CYP 3A4, CYP 2D6, and CYP 2C8, and its metabolism is mediated by hydrolase activity \[[@CR4], [@CR5]\]. The potential co-administration of inhibitors can lead to a potential increase in its levels \[[@CR4], [@CR5]\]. As remdesivir is a substrate of CYP 3A4, caution must be taken as it is co-administered with many drugs, including above, as CYP enzymes are involved in the metabolism of a wide range of medications. However, the initial data coming out shows no harmful effects of these drug-drug interactions, due to its rapid metabolism by hydrolase and esterase \[[@CR4], [@CR5]\]. We conducted thorough search of Embase, PubMed, Scopus, PsycINFO, SciELO, and Web of Science. Since the drug is new and the information available is scarce, this commentary aims to review the potential interactions of remdesivir (Table [1](#Tab1){ref-type="table"}).Table 1Drug interactions of remdesivirDrug interacting with remdesivirMechanism of actionEffect of drug interactionMetamizoleMetamizole induces CYP3A4 and CYP2B6, and remdesivir is a substrate for the sameLeads to decreased levels of remdesivir by rapid clearance. There is no effect on the metabolism of metamizole due to inhibition of CYP3A4 by remdesivirRifampicinRifampicin strongly induces CYP3A4 and P-gpLeads to decreased levels of remdesivir by rapid clearance. There is no effect on the metabolism of rifampicinRifabutinRifabutin strongly induces CYP3A4Leads to decreased levels of remdesivir by rapid clearance. There is no effect on the metabolism of rifabutinRifapentineRifapentine strongly induces CYP3A4Leads to decreased levels of remdesivir by rapid clearance. There is no effect on metabolism of rifapentineCarbamazepineCarbamazepine strongly induces CYP3A4 and UGT2B7Leads to decreased levels of remdesivir, no effect on carbamazepine as remdesivir does not affect UGT'sPhenytoinPhenytoin strongly induces CYP3A4Leads to decreased levels of remdesivir. There is no effect on phenytoin as CYP2C9 metabolizes itPhenobarbitonePhenobarbitone strongly induces CYP3A4Leads to decreased levels of remdesivir. There is no effect on phenytoin as CYP2C19, and CYP2C29 metabolize itPrimidonePrimidone is metabolized to phenobarbital and thus induces CYP3A4Leads to decreased levels of remdesivir. There is no effect on primidone by inhibition of CYP3A4 by remdesivir as it is not metabolized by itSt John's wortSt John's wort strongly induces CYP3A4It can lead to decreased levels of remdesivir. No effect is observed on metabolism of ST John's wortDexamethasoneDexamethasone strongly induces CYP3A4It can lead to decreased levels of remdesivir by rapid clearance but no effect on metabolism of dexamethasoneBetamethasoneBetamethasone strongly induces CYP3A4It can lead to decreased levels of remdesivir by rapid clearance but no effect on metabolism of betamethasone

Pharmacodynamic Interactions {#Sec1}
============================

Remdesivir has a low risk of significant pharmacodynamic interactions \[[@CR6]\].

Pharmacokinetic Interactions {#Sec2}
============================

Steroids like dexamethasone and betamethasone induce CYP3A4 and thus will result in the rapid clearance of remdesivir \[[@CR4]\]. Clinicians need to be cautious regarding this interaction. Rifampicin, rifabutin, and rifapentine strongly induce CYP3A4 enzyme \[[@CR7]\]. These medications are used in the treatment of tuberculosis and leprosy. Co-administration of these medications with remdesivir can lead to rapid clearance and a significant decrease in remdesivir levels \[[@CR6], [@CR7]\]. This combination should not be co-administered \[[@CR6], [@CR7]\]. Bosentan is a drug primarily used in the treatment of pulmonary arterial hypertension. As it is mainly metabolized by CYP 3A4 and CYP 2C9, 4, 5, it has the potential of interaction with remdesivir. Although remdesivir causes inhibition of CYP 3A4, it is not expected to affect bosentan's metabolism. However, as bosentan is an inducer of CYP 3A4, it can potentially cause decreased levels of remdesivir \[[@CR4]\]. Remdesivir does not interact with ambrisentan, epoprostenol, iloprost, macitentan, riociguat, selexipag, sildenafil, tadalafil, and treprostinil \[[@CR6]\]. Remdesivir has no known interactions with any bronchodilators and beta-blockers and antivirals including oseltamivir \[[@CR6]\]. Metamizole is a nonsteroidal anti-inflammatory drug (NSAID) used for chronic pain management in many countries. Metamizole gets hydrolyzed to 4-methylaminoantipyrine which is a substrate for CYP 3A4, 2B6, 2C8, and 2C9. No effect is expected due to remdesivir as it inhibits CYP3A4. However, as metamizole induces CYP3A4 moderately and CYP2B6 strongly in vitro, it can lead to depleted levels of remdesivir \[[@CR6]\].

In summary, since remdesivir is metabolized quickly, the risk of interactions is exceptionally low. As we deal with critically ill COVID-19 patients with underlying comorbidities, clinicians need to be careful about the co-administration of various drugs with remdesivir as listed above and keep an eye out for new data that comes out.
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